The Journal of Pediatrics
Volume 150, Issue 6 , Pages 631-634.e1 , June 2007

Nephropathy Advancing to End-Stage Renal Disease: A Novel Complication of Lysinuric Protein Intolerance

  • Laura M. Tanner, MD

      Affiliations

    • Department of Pediatrics, University of Turku, Turku, Finland
    • Corresponding Author InformationReprint requests: Laura M. Tanner, MD, Department of Pediatrics, University of Turku, Kiinamyllynkatu 4-8, 20520 Turku, Finland.
    • ,
  • Kirsti Näntö-Salonen, MD, PhD

      Affiliations

    • Department of Pediatrics, University of Turku, Turku, Finland
    • ,
  • Harri Niinikoski, MD, PhD

      Affiliations

    • Department of Pediatrics, University of Turku, Turku, Finland
    • ,
  • Timo Jahnukainen, MD, PhD

      Affiliations

    • Department of Pediatrics, University of Turku, Turku, Finland
    • ,
  • Päivi Keskinen, MD, PhD

      Affiliations

    • Department of Pediatrics, University Hospital of Tampere, and The Paediatric Research Centre, University of Tampere, Tampere, Finland
    • ,
  • Heikki Saha, MD, PhD

      Affiliations

    • Department of Internal Medicine, University Hospital of Tampere, Tampere, Finland
    • ,
  • Kristiina Kananen, MD, PhD

      Affiliations

    • Department of Internal Medicine, Kainuu Central Hospital, Kajaani, Finland
    • ,
  • Antero Helanterä, MD

      Affiliations

    • Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland
    • ,
  • Martti Metso, MD

      Affiliations

    • Department of Internal Medicine, Kanta-Häme Central Hospital, Hämeenlinna, Finland
    • ,
  • Marjatta Linnanvuo, MD

      Affiliations

    • Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
    • ,
  • Kirsi Huoponen, PhD

      Affiliations

    • Department of Medical Genetics, University of Turku, Turku, Finland.
    • ,
  • Olli Simell, MD, PhD

      Affiliations

    • Department of Pediatrics, University of Turku, Turku, Finland

Received 5 October 2006 ,Revised 28 November 2006 ,Accepted 31 January 2007.

References 

  1. Perheentupa J, Visakorpi J. Protein intolerance with deficient transport of basic amino acids. Lancet. 1965;2:813–816
  2. Rajantie J, Simell O, Perheentupa J. Basolateral-membrane transport defect for lysine in lysinuric protein intolerance. Lancet. 1980;1:1219–1221
  3. Norio R, Kekomäki M, Visakorpi JK. Lysinuric protein intolerance, an autosomal recessive disease. In: Clin Genet. 1971;p. 214–222
  4. Incerti B, Andria G, Parenti G, Sebastio G, Ghezzi M, Strisciuglio P, et al. Lysinuric protein intolerance—studies on 17 Italian patients. Am J Hum Genet. 1993;53:908
  5. Koizumi A, Shoji Y, Nozaki J, Noguchi A, Dakeishi M, Ohura T, et al. A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. Hum Mutat. 2000;16:270–271
  6. Torrents D, Estevez R, Pineda M, Fernandez E, Lloberas J, Shi YB, et al. Identification and characterization of a membrane protein (y(+)L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y(+)L—a candidate gene for lysinuric protein intolerance. J Biol Chem. 1998;273:32437–32445
  7. Torrents D, Mykkänen J, Pineda M, Feliubadalo L, Estevez R, de Cid R, et al. Identification of SLC7A7, encoding y(+)LAT-1, as the lysinuric protein intolerance gene. Nat Genet. 1999;21:293–296
  8. Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet. 1999;21:297–301
  9. Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE. Lysinuric protein intolerance. Am J Med. 1975;59:229–240
  10. Lukkarinen M, Parto K, Ruuskanen O, Vainio O, Käyhty H, Ölander RM, et al. B and T cell immunity in patients with lysinuric protein intolerance. Clin Exp Immunol. 1999;116:430–434
  11. Parenti G, Sebastio G, Strisciuglio P, Incerti B, Pecoraro C, Terracciano L, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr. 1995;126:246–251
  12. DiRocco M, Garibotto G, Rossi GA, Caruso U, Taccone A, Picco P, et al. Role of hematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr. 1993;152:437–440
  13. McManus DT, Moore R, Hill CM, Rodgers C, Carson DJ, Love AHG. Necropsy findings in lysinuric protein intolerance. J Clin Pathol. 1996;49:345–347
  14. Parto K, Kallajoki M, Aho H, Simell O. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance—case reports and autopsy findings of 4 pediatric patients. Hum Pathol. 1994;25:400–407
  15. Zager RA, Johannes G, Tuttle SE, Sharma HM. Acute amino acid nephrotoxicity. J Lab Clin Med. 1983;101:130–140
  16. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes. Diabetes. 2005;54:1238–1244
  17. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. J Am Soc.Nephrol. 2002;13:452A
  18. Mendiluce A, Bustamante J, Martin D, Santos M, Bustamante R, Pascual P, et al. Cystatin C as a marker of renal function in kidney transplant patients. Transplant Proc. 2005;37:3844–3847
  19. Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024–2031
  20. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition—a patient-level meta-analysis. Ann Int Med. 2003;139:244–252
  21. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. [Anon] Am J Kidney Dis. 2004;43:14–290
  22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  23. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease—a meta-analysis of patient-level data. Ann Int Med. 2001;135:73–87
  24. Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  25. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–140
  26. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899
  27. Ki CS, Kim IS, Kim JW, Lee NY, Kim SH, Lee KW, et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant. 2005;19:751–755
  28. Rebouche CJ, Engel AG. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes—evidence for alterations in tissue carnitine transport. J Clin Invest. 1984;73:857–867
  29. Takada G, Goto A, Komatsu K, Goto R. Carnitine deficiency in lysinuric protein intolerance—lysine-sparing effect of carnitine. Tohoku J Exp Med. 1987;153:331–334
  30. Korman SH, Raas-Rothschild A, Elpeleg O, Gutman A. Hypocarnitinemia in lysinuric protein intolerance. Mol Genet Metab. 2002;76:81–83
  31. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003;41:S13–S26
  32. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, et al. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther. 2000;68:238–249
  33. Golper TA, Goral S, Becker BN, Langman CB. L-carnitine treatment of anemia. Am J Kidney Dis. 2003;41:S27–S34
  34. Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder—National Kidney Foundation carnitine consensus conference. Am J Kidney Dis. 2003;41:868–876
  35. Patel S, Kwan JTC, McCloskey E, Mcgee G, Thomas G, Johnson D, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001;16:1863–1870
  36. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325:544–550
  37. Svedström E, Parto K, Marttinen M, Virtama P, Simell O. Skeletal manifestations of lysinuric protein intolerance—a follow-up study of 29 patients. Skeletal Radiol. 1993;22:11–16
  38. Parto K, Penttinen R, Paronen I, Pelliniemi L, Simell O. Osteoporosis in lysinuric protein intolerance. J Inherit Metab Dis. 1993;16:441–450
  39. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32:S142–S156
  40. Tanner L, Näntö-Salonen K, Niinikoski H, Erkkola R, Huoponen K, Simell O. Hazards associated with pregnancies and deliveries in lysinuric protein intolerance. Metabolism. 2006;55:224–231

 Supported by the European Genomics Initiative on Disorders of Plasma Membrane Amino Acid Transporters (EUGINDAT) and the Sigrid Juselius Foundation.

PII: S0022-3476(07)00118-7

doi: 10.1016/j.jpeds.2007.01.043

The Journal of Pediatrics
Volume 150, Issue 6 , Pages 631-634.e1 , June 2007

Article Tools

* Image Usage & Resolution